6 completed, 3 recruiting, 1 not yet recruiting, 1 terminated. 6 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Recruiting 2, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 5 | Completed 4, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia ABP-671 plus febuxostat Group 1, ABP-671 plus febuxostat Group 2, ABP-671 Group - Chronic Kidney Disease | Phase 2 | Not yet recruiting | Atom Therapeutics Co., Ltd | 80 | 2026-06-30 | 2026-06-04 |
| Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis ABP-745 Dose A, Placebo, ABP-745 Dose B - Atherosclerosis Cardiovascular Disease, ASCVD | Phase 2 | Recruiting | Atom Therapeutics Co., Ltd | 200 | 2026-04-23 | 2026-04-28 |
| Drug-Drug Interaction Study of ABP-671 in Gout Patients ABP-671 plus allopurinol - Gout Chronic, Gout | Phase 1 | Recruiting | Atom Therapeutics Co., Ltd | 20 | 2026-01-23 | 2026-04-14 |
| Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare ABP-745 Dose A, ABP-745 Dose B, Colchicine - Acute Gouty Arthritis, Gout Flare | Phase 2 | Recruiting | Atom Therapeutics Co., Ltd | 380 | 2025-08-26 | 2025-12-08 |
| Extension Study of ABP-671 in Participants With Gout ABP-671, Allopurinol - Gout | Phase 2 / Phase 3 | Terminated | Atom Therapeutics Co., Ltd | 43 | 2024-04-22 | 2025-07-16 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers ABP-745, Placebo - Gout, Acute Gout Flare | Phase 1 | Completed | Atom Therapeutics Co., Ltd | 90 | 2024-01-23 | 2025-08-17 |
| Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout ABP-671, Allopurinol, Placebo - Gout | Phase 2 / Phase 3 | Completed | Atom Therapeutics Co., Ltd | 300 | 2023-08-11 | 2025-12-22 |
| A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia ABP-671, Placebo - Gout, Hyperuricemia | Phase 2 | Completed | Atom Therapeutics Co., Ltd | 60 | 2020-11-27 | 2023-04-12 |
| Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects ABP-671 - Gout, Food-drug Interaction | Phase 1 | Completed | Atom Therapeutics Co., Ltd | 12 | 2020-05-22 | 2020-06-23 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 ABP-671, Placebo - Hyperuricemia, Gout | Phase 1 | Completed | Atom Therapeutics Co., Ltd | 27 | 2019-09-05 | 2020-02-12 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects ABP-671, Placebo - Gout, Hyperuricemia | Phase 1 | Completed | Atom Therapeutics Co., Ltd | 32 | 2018-10-17 | 2020-07-29 |
Gout (9) · Hyperuricemia (3) · Chronic Pain (1) · Renal Insufficiency, Chronic (1)
Allopurinol (3) · Colchicine (1)
United States (9) · Australia (6) · China (3) · Georgia (2) · Guatemala (2) · Taiwan (2)
Danielle Armas, M.D. (1) · Danielle Armas, MD (1)